Moderna is trading 8.79% higher at $249.00 amid a biotech-sector rally.
- The supplied context shows XBI up 2.13%, while broader U.S. markets are sharply higher.
- No new company-specific announcement clearly explains the November 4 move.
- Recent cancer-vaccine developments and November 6 earnings may be background, but available reporting does not establish them as the direct cause.